NASDAQ:AMGN - Amgen Stock Price, Forecast & News

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen declared a quarterly dividend on Wednesday, December 11th. Investors of record on Friday, February 14th will be paid a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 annualized dividend and a yield of 2.72%. The ex-dividend date is Thursday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.

Amgen announced that its Board of Directors has approved a share buyback program on Friday, February 2nd 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its shares are undervalued.

Amgen, Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, October, 29th. The medical research company reported $3.66 EPS for the quarter, topping the consensus estimate of $3.53 by $0.13. The medical research company earned $5.74 billion during the quarter, compared to analyst estimates of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. Amgen's revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period last year, the company earned $3.69 earnings per share. View Amgen's Earnings History.

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Amgen.

Amgen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.

22 equities research analysts have issued twelve-month price targets for Amgen's shares. Their forecasts range from $198.00 to $277.00. On average, they anticipate Amgen's stock price to reach $241.39 in the next year. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Price Targets for Amgen.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 10 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

Media coverage about AMGN stock has been trending very positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amgen earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Amgen.

Amgen saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 9,910,000 shares, an increase of 8.2% from the December 15th total of 9,160,000 shares. Based on an average trading volume of 2,130,000 shares, the short-interest ratio is currently 4.7 days. Currently, 1.7% of the company's stock are sold short. View Amgen's Current Options Chain.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), Cisco Systems (CSCO), AT&T (T), Home Depot (HD), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM).

Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Johanson Financial Advisors Inc. (0.20%), Candriam Luxembourg S.C.A. (0.15%), PGGM Investments (0.09%), Douglass Winthrop Advisors LLC (0.05%), Nisa Investment Advisors LLC (0.05%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Commerzbank Aktiengesellschaft FI, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Creative Financial Designs Inc. ADV, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Manning & Napier Group LLC, Fluent Financial LLC, Zurcher Kantonalbank Zurich Cantonalbank, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Exchange Traded Concepts LLC and Janney Montgomery Scott LLC. View Insider Buying and Selling for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $235.04.

Amgen has a market capitalization of $139.66 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

The official website for Amgen is http://www.amgen.com/.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]